Lanabecestat is an oral beta-secretase 1 cleaving enzyme inhibitor. A BACE inhibitor in theory would prevent the buildup of beta-amyloid and may help slow or stop the progression of Alzheimer's disease. From Wikipedia
Retrospective AI analysis of AMARANTH data revealed a 46% slower decline in slow-progressors treated with lanabecestat, prompting NHS Innovation East England to fund clinical integration.
